Haemophilus influenzae type b
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Haemophilus Influenzae Type b
Conditions
Haemophilus Influenzae Type b
Trial Timeline
Jul 1, 2008 → Oct 1, 2008
NCT ID
NCT00734565About Haemophilus influenzae type b
Haemophilus influenzae type b is a phase 1 stage product being developed by Novartis for Haemophilus Influenzae Type b. The current trial status is completed. This product is registered under clinical trial identifier NCT00734565. Target conditions include Haemophilus Influenzae Type b.
What happened to similar drugs?
2 of 9 similar drugs in Haemophilus Influenzae Type b were approved
Approved (2) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00734565 | Phase 1 | Completed |
Competing Products
10 competing products in Haemophilus Influenzae Type b
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Comparator: Modified Process Vaccine + Comparator: COMVAX™ | Merck | Phase 3 | 40 |
| Vaxelis + PedvaxHIB | Merck | Approved | 43 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 40 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 40 |
| Haemophilus influenza type b conjugate vaccine | Novartis | Approved | 43 |
| Hib-CRM197 + Hib-TT | Novartis | Phase 3 | 40 |
| Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine) | Novartis | Phase 3 | 40 |
| Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib) | Novartis | Phase 3 | 40 |
| Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine | Novartis | Phase 3 | 40 |
| DTaP-IPV/Hib | Sanofi | Pre-clinical | 26 |